Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
Seeking Alpha8/7/2026Neutral
HYPR
Hyperfine IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$94.69M
P/E Ratio
—
EPS
$-0.37
Beta
1.43
52W High
$2.22
52W Low
$0.85
50-Day MA
$1.17
200-Day MA
$1.19
Dividend Yield
—
Profit Margin
-210.70%
Forward P/E
—
PEG Ratio
—
About Hyperfine Inc
Hyperfine Inc. is a pioneering force in medical technology, renowned for developing the world’s first FDA-cleared portable MRI system, which significantly enhances diagnostic imaging accessibility at the point of care. By combining innovation with cost-efficiency, the company improves patient outcomes and facilitates rapid clinical decision-making. As healthcare continues to evolve, Hyperfine is strategically positioned to capture growth opportunities within the expanding imaging diagnostics market, presenting a compelling investment prospect for institutional investors focused on transformative healthcare solutions.
Fundamentals
| Revenue (TTM) | $16.54M |
| Gross Profit (TTM) | $8.50M |
| EBITDA | $-32.50M |
| Operating Margin | -216.90% |
| Return on Equity | -97.00% |
| Return on Assets | -38.80% |
| Revenue/Share (TTM) | $0.18 |
| Book Value | $0.35 |
| Price-to-Book | 2.58 |
| Price-to-Sales (TTM) | 5.73 |
| EV/Revenue | 3.909 |
| EV/EBITDA | -0.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 44.80% |
| Shares Outstanding | $90.99M |
| Float | $86.42M |
| % Insiders | 4.46% |
| % Institutions | 22.48% |
Historical Volatility
HV 10-Day
48.21%
HV 20-Day
47.21%
HV 30-Day
53.24%
HV 60-Day
74.49%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($2.03 target)
3
BuyLatest News
Hyperfine Q2 Earnings Call Highlights
Hyperfine NASDAQ: HYPR reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, as the portable MRI company cited growth across hospital, neurology office and international markets.
MarketBeat8/7/2026Neutral
Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care
GUILFORD, Conn.--(BUSINESS WIRE)--Multiple peer-reviewed publications in Journal of Neurosurgery and Stroke strengthen evidence for portable MRI in stroke and neurosurgical settings.
Business Wire7/30/2026Neutral
Hyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 2026. Management will host a corresponding conference call at 1:30 PM PT/4:30 PM ET.
Business Wire7/23/2026Neutral
Hyperfine Announces European Launch of Next-Generation Swoop® System
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine initiates the launch of the next-gen Swoop® system in Europe, beginning global expansion of its most advanced portable MRI technology. .
Business Wire7/1/2026Neutral
Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care
GUILFORD, Conn.--(BUSINESS WIRE)--Leading neurosurgeons will help guide the role of the Swoop® system in neurosurgical care, including workflow, product capabilities, and evidence.
Business Wire6/22/2026Neutral
Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces Swoop® system scan volume milestones at key hospitals and neurology clinics, demonstrating accelerating adoption across the US.
Business Wire6/18/2026Neutral
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha6/5/2026Neutral
Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
GUILFORD, Conn.--(BUSINESS WIRE)--PRIME study results show bedside portable MRI cut order-to-scan time vs conventional MRI and identified critical ED findings.
Business Wire5/22/2026Neutral
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Seeking Alpha5/13/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HYPR and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026